J
Joana M. Mack
Associate Professor
faculty
Peds Pediatrics, College of Medicine
8 h-index
37 pubs
212 cited
Research Areas
Biography and Research Information
OverviewAI-generated summary
Joana M. Mack researches vascular anomalies and related coagulopathies, particularly in pediatric populations. Her work includes investigating treatment modalities for these conditions, such as bleomycin sclerotherapy, and examining factors that predict patient outcomes. She has published on the pharmacokinetics of bleomycin and the multimodality treatment of head and neck vascular anomalies. Additionally, her research extends to sickle cell disease, exploring the impact of race-neutral predictive equations on spirometry results and the relationship between parental adverse childhood experiences and healthcare utilization in children with this condition. Mack's scholarship metrics include an h-index of 8, with 37 total publications and 203 total citations. She collaborates extensively with researchers at the University of Arkansas for Medical Sciences, including Shelley E. Crary, Divyaswathi Citla Sridhar, Suzanne Saccente, and Gresham T. Richter, with whom she shares multiple publications. Her recent activity indicates ongoing contributions to her fields of study.
Metrics
- h-index: 8
- Publications: 37
- Citations: 212
Selected Publications
-
ReInspire: A Phase 2 Study of Mutant-Selective PI3Kα Inhibitor, RLY-2608, in Adults and Children with PIK3CA-Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (2026)
-
Intracranial Hypotension in Pediatric Oncology Patients Following Lumbar Puncture: A Case Series (2025)
-
Creating a Roadmap for Longitudinal Quality Improvement Training in a Pediatric Residency Program (2025)
-
Burnout, Professional Fulfillment, Support, and Protected Time Among Pediatric Fellowship Program Directors (2025)
-
Parental Adverse Childhood Experiences and Health Care Use Among Children With Sickle Cell Disease (2025)
-
Effects of Adoption of Race‐Neutral Predictive Equations on Spirometry Results in Children With Sickle Cell Disease (2025)
-
Sociodemographic Characteristics of Patients Seen at Vascular Anomaly Centers in the United States (2025)
-
Hypercoagulability Evaluation in Pediatric Kidney Transplant Recipients to Optimize Outcomes (2024)
-
How we approach coagulopathy with vascular anomalies (2022)
-
Multimodality treatment of vascular anomalies of the head and neck (2022)
-
Pharmacokinetics of bleomycin sclerotherapy in patients with vascular malformations (2022)
Grants & Funding
- No FP attached UAMS ACHRI Flow Through Principal Investigator
Collaboration Network
Top Collaborators
Shelley E. Crary
University of Arkansas for Medical Sciences
15 shared publications
In database
- Pharmacokinetics of bleomycin sclerotherapy in patients with vascular malformations
- How we approach coagulopathy with vascular anomalies
- Bleomycin Sclerotherapy Is Laboratory Monitoring Necessary?
- Anticoagulation and vascular anomalies
- Hypercoagulability Evaluation in Pediatric Kidney Transplant Recipients to Optimize Outcomes
Showing 5 of 15 shared publications
Divyaswathi Citla Sridhar
University of Arkansas for Medical Sciences
4 shared publications
In database
- Parental Adverse Childhood Experiences and Health Care Use Among Children With Sickle Cell Disease
- Poor School Performance As an Indicator of Severity of Sickle Cell Disease
- Mental health in persons with von Willebrand disease in the United States – a large national database study
- Effects of Vitamin D Stoss Dosing in Patients with Sickle Cell Disease
Bethany Verkamp
Cincinnati Children's Hospital Medical Center (US)
3 shared publications
- Early response markers predict survival after etoposide-based therapy of hemophagocytic lymphohistiocytosis
- Bleomycin Sclerotherapy Is Laboratory Monitoring Necessary?
- Early Response Parameters during Etoposide-Based Hemophagocytic Lymphohistiocytosis Treatment in Children Predict Early Mortality
Austin N. DeHart
Phoenix Children's Hospital (US)
2 shared publications
- Bleomycin Sclerotherapy Is Laboratory Monitoring Necessary?
- Surveillance Chest X-Ray and Pulmonary Function Testing in Patients Undergoing Intralesional Bleomycin in the Treatment of Vascular Malformations
P. Spencer Lewis
Arkansas Children's Hospital (US)
2 shared publications
- Bleomycin Sclerotherapy Is Laboratory Monitoring Necessary?
- Surveillance Chest X-Ray and Pulmonary Function Testing in Patients Undergoing Intralesional Bleomycin in the Treatment of Vascular Malformations
Gresham T. Richter
University of Arkansas for Medical Sciences
2 shared publications
In database
- Pharmacokinetics of bleomycin sclerotherapy in patients with vascular malformations
- Multimodality treatment of vascular anomalies of the head and neck
Joanne Yacobovich
Schneider Children's Medical Center (IL)
2 shared publications
- Early response markers predict survival after etoposide-based therapy of hemophagocytic lymphohistiocytosis
- Early Response Parameters during Etoposide-Based Hemophagocytic Lymphohistiocytosis Treatment in Children Predict Early Mortality
Brenton Francisco
2 shared publications
- Early response markers predict survival after etoposide-based therapy of hemophagocytic lymphohistiocytosis
- Early Response Parameters during Etoposide-Based Hemophagocytic Lymphohistiocytosis Treatment in Children Predict Early Mortality
Tucker Blackledge
Arkansas Children's Hospital (US)
2 shared publications
- Early response markers predict survival after etoposide-based therapy of hemophagocytic lymphohistiocytosis
- Early Response Parameters during Etoposide-Based Hemophagocytic Lymphohistiocytosis Treatment in Children Predict Early Mortality
Dafna Brik Simon
Tel Aviv University (IL)
2 shared publications
- Early response markers predict survival after etoposide-based therapy of hemophagocytic lymphohistiocytosis
- Early Response Parameters during Etoposide-Based Hemophagocytic Lymphohistiocytosis Treatment in Children Predict Early Mortality
Adi Zoref‐Lorenz
Meir Medical Center (IL)
2 shared publications
- Early response markers predict survival after etoposide-based therapy of hemophagocytic lymphohistiocytosis
- Early Response Parameters during Etoposide-Based Hemophagocytic Lymphohistiocytosis Treatment in Children Predict Early Mortality
Michael B. Jordan
University of Cincinnati (US)
2 shared publications
- Early response markers predict survival after etoposide-based therapy of hemophagocytic lymphohistiocytosis
- Early Response Parameters during Etoposide-Based Hemophagocytic Lymphohistiocytosis Treatment in Children Predict Early Mortality
Suzanne L Saccente
Arkansas Children's Hospital (US)
2 shared publications
- Poor School Performance As an Indicator of Severity of Sickle Cell Disease
- Effects of Vitamin D Stoss Dosing in Patients with Sickle Cell Disease
Bryan A. Sisk
St. Louis Children's Hospital (US)
2 shared publications
- Sociodemographic Characteristics of Patients Seen at Vascular Anomaly Centers in the United States
- ReInspire: A Phase 2 Study of Mutant-Selective PI3Kα Inhibitor, RLY-2608, in Adults and Children with PIK3CA-Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
Vivian Y. Chang
University of California, Los Angeles (US)
2 shared publications
- Sociodemographic Characteristics of Patients Seen at Vascular Anomaly Centers in the United States
- ReInspire: A Phase 2 Study of Mutant-Selective PI3Kα Inhibitor, RLY-2608, in Adults and Children with PIK3CA-Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
Similar Researchers
Based on overlapping research topics
Kathleen Danielle Aldrich
University of Arkansas for Medical Sciences
Child and Adolescent Health
Cancer Treatment and Pharmacology
Health disparities and outcomes
David P. Douglass
University of Arkansas for Medical Sciences
Child and Adolescent Health
Cancer Treatment and Pharmacology
Pharmacological Effects and Toxicity Studies
Erhan Ararat
University of Arkansas for Medical Sciences
Child and Adolescent Health
Pharmacological Effects and Toxicity Studies
Health disparities and outcomes
Beatriz Cuevas
University of Arkansas at Fayetteville
Cancer Treatment and Pharmacology
Pharmacological Effects and Toxicity Studies
Health disparities and outcomes
David K. Wilson
University of Arkansas for Medical Sciences
Child and Adolescent Health
Cancer Treatment and Pharmacology
Health disparities and outcomes
Kimo C. Stine
University of Arkansas for Medical Sciences
Child and Adolescent Health
Cancer Treatment and Pharmacology
Pharmacological Effects and Toxicity Studies